What is HC Wainwright’s Forecast for VVOS Q1 Earnings?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – HC Wainwright issued their Q1 2026 EPS estimates for Vivos Therapeutics in a report released on Friday, April 17th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Vivos Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($1.18) EPS.

VVOS has been the topic of several other reports. Ascendiant Capital Markets cut their price target on shares of Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $2.58.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $1.03 on Wednesday. Vivos Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $7.95. The stock has a market cap of $13.89 million, a PE ratio of -0.50 and a beta of 6.93. The firm’s 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.93. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.24 and a current ratio of 0.24.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Wednesday, April 15th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.08). The business had revenue of $3.82 million for the quarter, compared to the consensus estimate of $7.10 million. Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.During the same period in the previous year, the firm earned ($2.22) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acorn Wealth Advisors LLC purchased a new position in Vivos Therapeutics in the fourth quarter valued at about $30,000. XTX Topco Ltd purchased a new position in Vivos Therapeutics in the second quarter valued at about $65,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the second quarter valued at about $220,000. DRW Securities LLC boosted its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares during the last quarter. Finally, Connective Capital Management LLC purchased a new position in Vivos Therapeutics in the third quarter valued at about $620,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the acquisition, the insider owned 1,353,625 shares in the company, valued at $1,813,857.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.10% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.